
    
      The primary objective is to evaluate the PK profile of a single-dose of 140 mg subcutaneous
      (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate
      asthma. The secondary objective is to evaluate the safety and tolerability of MEDI9929 and to
      evaluate the immunogenicity of MEDI9929 (AMG 157). The exploratory objective is to evaluate
      the effect of MEDI9929 (AMG 157) on pulmonary function
    
  